In:
Future Cardiology, Future Medicine Ltd, Vol. 14, No. 3s ( 2018-05), p. 31-37
Abstract:
Aim: To evaluate the clinical profile and effectiveness/safety of patients taking rivaroxaban in clinical practice. Methods: Retrospective study that included patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke between January 2012 and December 2016 in a tertiary hospital in Spain. Results: A total of 142 patients (median age 78 years, 40.1% men, 32.4% creatinine clearance 〈 50 ml/min; 96.5% CHA 2 DS 2 -VASc ≥2; 44.3% HAS-BLED ≥3) were included. Only two patients had a thromboembolic event (in both cases ischemic stroke) and three patients had major bleeding (rates of 1.3 and 1.9 events/100 patient years, respectively). Conclusion: Data regarding effectiveness and safety in our cohort were consistent with previous studies, showing that rivaroxaban can be effective and safely used in our setting.
Type of Medium:
Online Resource
ISSN:
1479-6678
,
1744-8298
DOI:
10.2217/fca-2018-0024
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2018